MPM.L Regulatory News (MPM)

8 Mar 2006 07:03

Minster Pharmaceuticals PLC08 March 2006 For Immediate Release 8 March 2006 MINSTER PHARMACEUTICALS PLC ("Minster" or "the Company") Appointment of Nomura Code Securities Ltd as Nominated Adviser and Broker Minster Pharmaceuticals plc (AIM: MPM), the drug development companyspecialising in neurological and psychiatric disorders, is pleased to announcethe appointment with immediate effect of Nomura Code Securities Ltd as theCompany's nominated adviser and broker. ENDS For further information: Minster Pharmaceuticals plc Tel: +44 (0) 1799 506623Paul Sharpe, Chief Executive OfficerRobert Aubrey, Chief Financial Officer Nomura Code Securities Ltd Tel: +44 (0) 20 7024 2004Chris Collins Buchanan Communications Tel: +44 (0) 20 7466 5000Mark Court Rebecca Skye Dietrich Notes for editors: About Minster Pharmaceuticals plc Minster Pharmaceuticals was co-founded in January 2001 by Paul Sharpe MD, aformer head of the Neuroscience Development Team at SmithKline Beecham, and byRobert Aubrey, who has extensive senior management experience. Minster, whichwas initially named BioPartners Ltd, was formed on the acquisition fromGlaxoSmithKline of the worldwide development rights of two compounds, tonabersatand sabcomeline, which have already benefited from substantial investment byGSK. Tonabersat is the most advanced compound in an exciting new class of drugscalled gap junction blockers, which have significant potential in the preventionof migraine. Sabcomeline, a muscarinic partial agonist, has potential in thetreatment of chronic schizophrenia. Both compounds benefit from comprehensivesafety tolerance data as a result of investment by GSK. Minster's core competence is in drug development. In addition to progressing thedevelopment of tonabersat and sabcomeline, the company has the capability totake on further compounds by acquisition or by in-licensing. Minster joined the AIM market in February 2005 and trades under the symbol MPM.For further information please visit www.minsterpharma.com. This information is provided by RNS The company news service from the London Stock Exchange